Merrimack Income Before Tax vs Interest Expense Analysis
MACK Stock | USD 14.98 0.24 1.63% |
Merrimack Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Merrimack Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Merrimack Pharmaceuticals is a good investment. Please check the relationship between Merrimack Pharmaceuticals Income Before Tax and its Interest Expense accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.
Income Before Tax vs Interest Expense
Income Before Tax vs Interest Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Merrimack Pharmaceuticals Income Before Tax account and Interest Expense. At this time, the significance of the direction appears to have pay attention.
The correlation between Merrimack Pharmaceuticals' Income Before Tax and Interest Expense is -0.76. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Merrimack Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Merrimack Pharmaceuticals' Income Before Tax and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Merrimack Pharmaceuticals are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Income Before Tax i.e., Merrimack Pharmaceuticals' Income Before Tax and Interest Expense go up and down completely randomly.
Correlation Coefficient | -0.76 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Merrimack Pharmaceuticals income statement and is an important metric when analyzing Merrimack Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Most indicators from Merrimack Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merrimack Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.Tax Provision is expected to rise to about 12.6 K this year, although the value of Selling General Administrative will most likely fall to 2,067.
2023 | 2024 (projected) | Total Operating Expenses | 2.2M | 2.1M | Cost Of Revenue | 400.5K | 380.5K |
Merrimack Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Merrimack Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Merrimack Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 13.4M | 13.4M | 13.4M | 13.5M | 14.3M | 10.9M | |
Total Assets | 20.1M | 16.8M | 14.7M | 19.8M | 19.2M | 18.2M | |
Other Current Liab | 2.5M | 647K | 442K | 401K | 367K | 348.7K | |
Total Current Liabilities | 2.8M | 770K | 562K | 589K | 441K | 419.0K | |
Total Stockholder Equity | 17.3M | 16.0M | 14.2M | 19.2M | 18.7M | 19.7M | |
Net Debt | (16.6M) | (14.0M) | (14.2M) | (19.4M) | (6.0M) | (5.7M) | |
Retained Earnings | (540.6M) | (543.6M) | (546.1M) | (547.6M) | (548.8M) | (576.3M) | |
Accounts Payable | 271K | 123K | 120K | 188K | 74K | 70.3K | |
Cash | 16.6M | 14.0M | 14.2M | 19.4M | 6.0M | 5.7M | |
Non Current Assets Total | 1.4M | 232K | 66K | 8K | 4K | 3.8K | |
Non Currrent Assets Other | 1.4M | 232K | 66K | 8K | 4K | 3.8K | |
Cash And Short Term Investments | 16.6M | 14.0M | 14.2M | 19.4M | 18.9M | 17.9M | |
Liabilities And Stockholders Equity | 20.1M | 16.8M | 14.7M | 19.8M | 19.2M | 18.2M | |
Non Current Liabilities Total | 14.9M | 271K | 123K | 120K | 589K | 0.0 | |
Other Current Assets | 2.1M | 2.5M | 480K | 389K | 309K | 293.6K | |
Other Stockholder Equity | 556.6M | 558.3M | 558.9M | 565.5M | 566.2M | 507.8M | |
Total Liab | 2.8M | 770K | 562K | 589K | 441K | 419.0K | |
Total Current Assets | 18.7M | 16.5M | 14.7M | 19.8M | 19.2M | 18.2M | |
Other Assets | 2.7M | 1.4M | 232K | 66K | 8K | 0.0 | |
Net Tangible Assets | 17.3M | 16.0M | 14.2M | 19.2M | 22.1M | 23.2M | |
Retained Earnings Total Equity | (523.3M) | (540.6M) | (543.6M) | (547.6M) | (492.9M) | (517.5M) | |
Capital Surpluse | 580.8M | 556.6M | 558.3M | 565.5M | 650.4M | 625.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merrimack Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.Note that the Merrimack Pharmaceuticals information on this page should be used as a complementary analysis to other Merrimack Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Merrimack Stock analysis
When running Merrimack Pharmaceuticals' price analysis, check to measure Merrimack Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merrimack Pharmaceuticals is operating at the current time. Most of Merrimack Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Merrimack Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merrimack Pharmaceuticals' price. Additionally, you may evaluate how the addition of Merrimack Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Merrimack Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merrimack Pharmaceuticals. If investors know Merrimack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merrimack Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.08) | Return On Assets (0.07) | Return On Equity (0.06) |
The market value of Merrimack Pharmaceuticals is measured differently than its book value, which is the value of Merrimack that is recorded on the company's balance sheet. Investors also form their own opinion of Merrimack Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Merrimack Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merrimack Pharmaceuticals' market value can be influenced by many factors that don't directly affect Merrimack Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merrimack Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Merrimack Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merrimack Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.